Navigation Links
Aethlon Medical to Host Investor Event on January 20, 2011
Date:1/5/2011

SAN DIEGO, Jan. 5, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it will host an investor event at 5:30 pm PST on January 20, 2011 at the Hyatt Regency La Jolla at Aventine located at 3777 La Jolla Village Drive, San Diego, California, 92122.

(Photo:  http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

Jim Joyce, Chairman and Chief Executive Officer of Aethlon Medical, Inc., will present the company's strategic goals, product roadmap, and key milestones for 2011 and will introduce new company President, Rod Kenley.  Additionally, Bud Leedom, President and Director of Research at California Equity Research, will discuss current investment trends and his recently initiated coverage of the company.

For those attendees who are travelling to San Diego, a special room rate of $149 is available at the Hyatt Regency La Jolla by contacting their reservations department at 858.552.1234 and requesting the "BIOCOM" corporate rate.  As seating is limited, please contact Charlene Owen or John Salvador to RSVP at:Charlene Owen858.459.7800 x 305cowen@aethlonmedical.comJohn P. SalvadorDirector, Communications & Investor Relations858.459.7800 x 307jps@aethlonmedical.comAbout Aethlon MedicalAt Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.  However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union.  In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

  1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
  2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.  
  3. Human Immunodeficiency Virus (HIV):  Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
  4. Bioterror and Pandemic Threats:  Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
2. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
3. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
4. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
5. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
6. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
7. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
8. Aethlon Medical Reestablishes Biodefense Programs
9. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
10. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
11. Aethlon Medical Names Rod Kenley President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... YORK , Feb. 27, 2017 /PRNewswire/ ... Michael P. Vallely , MBBS, PhD, FRACS, of  ... University of Sydney will be published ...  Journal of the American College of Cardiology ... "no-touch" beating heart bypass surgery technique (anOPCABG) ...
(Date:2/27/2017)... Feb. 27, 2017  International Biophysics Corporation, a global medical ... today announced a 34% revenue growth in 2016 when compared ... unit sales.  This growth was fueled by its AffloVest® sales ... to the expansion of its global sales of surgical product ... CEO, "As we enter our 25 th year in ...
(Date:2/27/2017)... , Feb. 27, 2017  RegeneRx Biopharmaceuticals, ... clinical-stage drug development company focused on tissue protection, ... for RGN-137, GtreeBNT Co., Ltd., received a positive ... 3 clinical trial design for RGN-137 to treat ... healing gel that incorporates Thymosin beta 4 ("Tß4") ...
Breaking Medicine Technology:
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... mass and overall body strength, which often leads to a host of health ... Journal of the American Geriatrics Society discovered that good overall muscle strength ...
(Date:2/27/2017)... ... February 27, 2017 , ... Robert E. Burke, MD, PhD, had ... his impoverished upbringing and life experiences could have led him down a much different ... Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a personal account of ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Much attention has ... for women who become dependent on opioid painkillers has fallen short. From 1999 until ... to a 237% increase in fatal overdoses in male populations.(1) , The proportion of ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Elisa Guajardo Carothers is not your typical author. ... studying to become a nun. Now, she writes about God, when she isn’t swimming as ... BC and AD, Here is BS! (Before Satan),” she offers a comedic look at the ...
(Date:2/27/2017)... Yorba Linda, Ca (PRWEB) , ... February 27, ... ... Coulter Life Sciences, provides an overview on laser diffraction analysis as a tool ... highlighting its capabilities, significance and potential to obtain improved results and novel scientific ...
Breaking Medicine News(10 mins):